pre-eclampsia/tyrosine

Веза се чува у привремену меморију

Изаберите тип сортирања

Страна 1 од 1022 резултати

Thrombin enhances soluble Fms-like tyrosine kinase 1 expression in trophoblasts; possible involvement in the pathogenesis of preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE To investigate the possible impact of thrombin on soluble Fms-like tyrosine kinase 1 (sFlt-1) expression in trophoblasts. METHODS Experimental. METHODS University hospital laboratory. METHODS A trophoblast cell line (HRT-8/SVneo) was treated with thrombin, protease-activated receptor 1

Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The primary placental defect in preeclampsia is shallow trophoblast invasion of the decidua leading to incomplete vascular transformation and inadequate uteroplacental perfusion. Soluble fms-like tyrosine kinase-1 (sFlt-1) seems to interfere with these events by inhibiting local angiogenesis and/or

Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE The purpose of this study was to determine if maternal serum concentrations of placenta growth factor (PlGF) and soluble Fms-like tyrosine kinase 1 receptor (s-Flt1) are more abnormal in patients with severe preeclampsia compared with mild preeclampsia. METHODS Serum samples were collected

Nutraceutical Targeting of Placental Synthesis of Soluble Fms-Like Tyrosine Kinase- 1 (sFlt-1) as Strategy for Preventing and Controlling Pre-eclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The primary driving force in preeclampsia (PE) appears to be excessive secretion of fms-like tyrosine kinase-1 (sFlt-1), a truncated decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) that induces systemic endotheliopathy by depriving endothelial cells of

Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Increased maternal plasma levels of proinflammatory cytokines as well as the anti-angiogenic agents soluble fms-like tyrosine kinase 1 (sFlt-1) and endoglin (sEng) are associated with promoting vascular dysfunction leading to the maternal syndrome of preeclampsia. OBJECTIVE Nulliparous

Downregulation of receptor tyrosine kinase-like orphan receptor 1 in preeclampsia placenta inhibits human trophoblast cell proliferation, migration, and invasion by PI3K/AKT/mTOR pathway accommodation.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Invasive deficiency of the trophoblast and poor remodeling of the uterine spiral arteries were probably the primary pathogenesis causes of preeclampsia (PE). The expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) during embryogenesis had been previously confirmed and

Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE We measured maternal serum soluble fms-like tyrosine kinase 1 concentrations across pregnancy and immediately postpartum in women who developed preeclampsia and normal pregnant women. METHODS This was a nested case control study of 113 normal pregnant women and 55 women with

Variable expression of soluble fms-like tyrosine kinase 1 in patients at high risk for preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE To explore angiogenic factor differences in preeclamptic patients according to the absence or presence of underlying vascular disease. METHODS We prospectively compared serum soluble fms-like tyrosine kinase 1 (sFlt1), soluble endoglin, and placental growth factor (PlGF) from 41

Placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The pathophysiology of preeclampsia remains largely unknown. A number of circulating placenta-produced factors have been implicated in causing the endothelial dysfunction and the clinical phenotype characteristic of preeclampsia. OBJECTIVE Determination of serum levels of placental soluble fms-like

Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE Performance evaluation of the novel BRAHMS KRYPTOR soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) assays. METHODS Intra- and inter-assay imprecision, functional sensitivity, linearity in dilution, method comparison, and diagnostic capacity were

Lymphokine-activated killer cells induced from decidual lymphocytes reduce the angiogenic activity of trophoblasts by enhancing the release of soluble fms-like tyrosine kinase-1 from trophoblasts: an implication for the pathophysiology of preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

T helper (Th)1 cytokine-predominating status and compromised placental vasculature is thought to be central to the pathogenesis of preeclampsia. However, it remains to be clarified how these two phenomena relate to each other. We have reported that lymphokine-activated killer (LAK) cells induced

First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE The aim of this investigation was to assess soluble endoglin (sEng) and soluble fms-like tyrosine kinase-1 (sFlt1) as first-trimester serum markers to predict preeclampsia. METHODS First-trimester sera were obtained from 46 women with subsequent late-onset preeclampsia and from 92

Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE To estimate whether alterations in plasma levels of the proangiogenic proteins placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A), and the antiangiogenic protein soluble fms-like tyrosine kinase-1 (sFlt1) were more pronounced in early-onset than in late-onset

Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE To investigate the maternal plasma concentration of soluble fms-like tyrosine kinase-1 (sFlt-1) and free vascular endothelial growth factor (free-VEGF) at 11 to 13 weeks of gestation in patients destined to develop preeclampsia (PE) and to examine whether any possible differences in

Preeclampsia Screening Using the Ratio of Soluble FMS-Like Tyrosine Kinase-1 to Placental Growth Factor During Pregnancy in Pregnant Korean Women

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Background: We retrospectively investigated soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratios and screen-positive rates according to cutoff values for preeclampsia risk assessment based on the number of

Претходна
1
2
3
4
5
6
...
68
69
Следећи

Придружите се нашој
facebook страници

Herbal & Natural Medicine

Најкомплетнија база лековитог биља подржана науком

Ради на 55 језика
Биљни лекови потпомогнути науком
Препознавање биљака по слици
Интерактивна ГПС мапа - означите биље на локацији (ускоро)
Читајте научне публикације повезане са вашом претрагом
Претражите лековито биље по њиховим ефектима
Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима